Immunotherapy has prompted a paradigm shift in advanced non-small cell lung cancer
(NSCLC) treatment, by demonstrating superior efficacy to chemotherapy alone both in …

Tumor-associated macrophages (TAMs) are the main component of tumor-infiltrating
immune cells in the lung tumor microenvironment. TAMs recruited to the lung cancer can …

Background Natural killer (NK) cells play a crucial role in tumor immunosurveillance through
their cytotoxic effector functions and their capacity to interact with other immune cells to build …

Immune checkpoint inhibitors (ICIs) are new and promising therapeutic agents for non-small
cell lung cancer (NSCLC). However, along with demonstrating remarkable efficacy, ICIs can …

Purpose This prospective study aimed (1) to assess the non-small cell lung cancer (NSCLC)
evolutive patterns to immunotherapy using FDG-PET and (2) to describe their association …

As single-cell RNA sequencing (scRNA-seq) has emerged as a great tool for studying
cellular heterogeneity within the past decade, the number of available scRNA-seq datasets …

Immune checkpoint blockade (ICB) expands the therapeutic options for metastatic lung
cancer nowadays representing a standard frontline strategy as monotherapy or combination …

The impact of the tumor immune microenvironment on overall survival in non‐small cell lung
cancer (NSCLC) has been studied, but there is little information on its relevance for risk of …

With over a million deaths every year around the world, lung cancer is found to be the most
recurrent cancer among all types. Nonsmall cell lung carcinoma (NSCLC) amounts to about …

Malignant pleural effusions, arising from either primary mesotheliomas or secondary
malignancies, heralds advanced disease and poor prognosis. Current treatments, including …